Table 1.
Ongoing clinical trials using checkpoint inhibitors in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
| Clinical trial identifier | Checkpoint target | Disease subsets | Combined therapy | Phase, status |
|---|---|---|---|---|
| NCT03381118 | PD-1 | Elderly AML | Cytarabine, haploidentical donor PBSC | 2, recruiting |
| NCT01096602 | PD-1 | AML | DC vaccine | 2, active not recruiting |
| NCT01822509 | CTLA-4 or PD-1 | Heme malignancy including AML post-allo transplant | None | 1, recruiting |
| NCT01919619 | CTLA-4 | Post-auto SCT leukemia | Lenalidomide | 1, recruiting |
| NCT01953692 | PD-1 | MDS | None in MDS arm | 1, active not recruiting |
| NCT02117219 | PD-L1 PD-L1 + CTLA-4 | MDS | Azacitidine | 1, recruiting |
| NCT02275533 | PD-1 | AML (remission) | None | 2, recruiting |
| NCT02397720 | PD-1 PD-1 + CTLA-4 | AML | Azacitidine | 2, recruiting |
| NCT02464657 | PD-1 | MDS + AML | Idarubicin + cytarabine | 1/2, recruiting |
| NCT02530463 | PD-1 CTLA-4 PD-1 + CTLA-4 | MDS + AML | Azacitidine | 2, recruiting |
| NCT02532231 | PD-1 | AML | None | 2, recruiting |
| NCT02599649 | PD-1 | MDS | KIR2DL1/2L3 azacitidine | 2, active not recruiting |
| NCT02708641 | PD-1 | AML elderly | None | 2, recruiting |
| NCT02768792 | PD-1 | R/R AML | Cytarabine | 2, recruiting |
| NCT02771197 | PD-1 | High-risk AML not eligible for hematopoietic stem cell transplantation (HSCT) |
|
2, recruiting |
| NCT02775903 | PD-L1 | MDS + AML | Azacitidine | 2, active not recruiting |
| NCT02845297 | PD-1 | AML + R/R AML | Azacitidine | 2, recruiting |
| NCT02846376 | CTLA-4 ± PD-1 | MDS + AML | None | 1, recruiting |
| NCT02890329 | CTLA-4 | MDS + AML | Decitabine | 1, recruiting |
| NCT02935361 | PD-L1 | MDS, recurrent AML | Guadecitabine | 1/2, recruiting |
| NCT02936752 | PD-1 | MDS | Entinostat | 1, recruiting |
| NCT02953561 | PD-L1 | AML | Azacitidine | 1/2, recruiting |
| NCT02981914 | PD-1 | AML, MDS | None | 1, recruiting |
| NCT02985554 | PD-1 | Post-allo SCT leukemia | None | 1, recruiting |
| NCT02996474 | PD-1 | R/R AML | Decitabine | 1, recruiting |
| NCT03059485 | PD-L1 | AML, remission | DC/AML fusion vaccine | 2, recruiting |
| NCT03066648 | PD-1 TIM-3 PD-1 + TIM-3 | MDS + AML | Decitabine | 1, recruiting |
| NCT03092674 | PD-1 | AML or high risk MDS | Azacitidine, cytarabine, decitabine, and midostaurin | 2/3, recruiting |
| NCT03094637 | PD-1 | MDS | Azacitidine | 2, recruiting |
| NCT03146468 | PD-1 | Post-allo SCT leukemia | None | 2, recruiting |
| NCT03154827 | PD-L1 | AML | CXCR4 | 1b/2, recruiting |
| NCT03259516 | PD-1 | MDS |
|
1/2, recruiting |
| NCT03286114 | PD-1 | MDS, AML, ALL | None | 1, recruiting |
| NCT03291353 | PD-1 | refractory AML | None | 1, recruiting |
| NCT03358719 | PD-1 | MDS, AML, chronic myelomonocytic leukemia, and refractory anemia | DEC-205/NY-ESO-1 CDX-1401 decitabine poly OC:C | 1, recruiting |
| NCT03390296 | PD-L1 OX40 4-1BB | AML |
|
2, recruiting |
| NCT03395873 | PD-L1 | AML | Decitabine | 1, recruiting |